Who We Are
Pharma Capital Partners is led by highly experienced industry executives with extensive expertise in investment management, life science drug development, portfolio management and strategic marketing. Our senior partners have managed large R&D organizations and significant product portfolios for leading pharmaceutical and biotechnology companies. Collectively, we have been instrumental in bringing more than 60 new pharmaceutical products to the market across diverse therapeutic areas.
This depth of product development and commercial success provides us with the perspective to identify and make investments in high-value therapeutic assets and advance those assets through key value inflection points that mitigate safety risks and demonstrate therapeutic efficacy in proof-of-concept clinical studies. With more than ten decades of combined experience in all aspects of drug development, our partners have cultivated a global network of personal relationships that reach deep into the entrepreneurial, biotech, academic and pharmaceutical worlds.
Dr Radomir Julina - Managing General Partner
Radomir is Managing General Partner at Pharma Capital Partners and leads the Fund’s overall business activities. Radomir has been working in the pharmaceutical, biotech and private equity sectors for the last 25+ years. He has built a significant track record in areas ranging from pharmaceutical operations, drug development, the management of global drug development programs, and the building of efficient virtual drug development organizations, to investment finance. His experience in global private equity and virtual drug development, in particular, have helped shape the Fund’s investment approach and provides a model for success.
Prior to forming Pharma Capital Partners, Radomir was Managing Director at Celtic Pharma Management L.P., a $450 million private equity investment fund focused on evaluating and funding late-stage clinical assets. He joined Celtic Pharma Management L.P., from Protodigm Ltd., a virtual drug development company in the UK, where he was co-founder and Director. Protodigm was a spin-off from Hoffmann-La Roche AG, formed with the objective of creating and testing the accelerated novel time- and cost-efficient processes for drug development based on global strategic outsourcing and the virtual drug development company model. The Protodigm team successfully developed four novel product candidates across four different therapeutic areas from IND to NDA in less than four years – significantly beating industry benchmarks for time and funds invested.
Before Protodigm, Radomir was Head of New Molecular Entity Planning at Roche in the U.S. In this role, he worked with multidisciplinary international teams that were responsible for global strategic planning, project management and the outsourcing and partnering of large-scale global drug development programs. Before his assignment in the U.S., Radomir held various management positions at Hoffmann-La Roche AG in Switzerland in drug development, supply chain management and pharmaceutical operations. Prior, Radomir was Head of R&D and Vice-Chairman of the Board at Carbogen Laboratories AG in Switzerland, a drug development services company, which he co-founded. He holds a Ph.D. in Organic Chemistry from the University of Zurich, Switzerland. Radomir has a passion for drug development, building successful virtual organizations and investment finance.
Hugh MacMillan - General Partner & CFO
Hugh MacMillan focuses on financial management of Pharma Capital Partners’ funds and operations, and deal negotiations and legal structuring of PCP’s business contracts with its investors and research partners. He has twenty-five years of industry experience as a public and private equity and debt investor, investment banker, partnership operator, board member and strategy consultant.
He has developed a broad perspective, with first-hand experience of thousands of real-life case studies of developing companies' successes and mistakes, over a wide array of sectors and financial, operational, and regulatory situations.
Mr. MacMillan also brings specific strengths in strategic planning including decision tree analysis and contingent planning, factoring in multiple development and outcome scenarios for primary assets individually, and for companies and investment portfolios as a whole. He understands the fund-raising challenges for growth companies and has raised over US$1 billion in multiple investment and project-specific funds from institutional and private investors. In addition, over the past seven years prior to joining Pharma Capital Partners he developed an expertise in securities and corporate law, specifically in corporate and transactional structuring and authoring of complex contracts for entities and operations in the U.S., Canada, and Caribbean.
Prior to starting his own partnerships, he was focused on Public Company investments as Vice President for the Capital Group Companies, one of the world’s oldest and largest investment management organizations, with $1.5 trillion in assets under management. He received his BA with High Honors from Wesleyan University - with concentrations in Chemistry and Economics in 1991, an MBA with a concentration in Finance from Stanford University's Graduate School of Business in 1995, and a Chartered Financial Analyst (CFA) designation in 1999.
Michael G Shulman MD – Managing Director Clinical Science & Development Strategy
During more than a quarter century devoted to industry drug development for serious unmet medical needs, Michael was closely associated with development, regulatory approval, new indications, marketing launch and post-marketing studies of 11 products including Sandimmune®, Neoral®, CellCept®, DynaCirc®, Celsior®, L-Asparaginase®, and Krystexxa® (pegloticase).
In addition to Medical Affairs responsibilities at Sandoz Pharmaceuticals Corporation and clinical development roles at Syntex Development Research, Michael was Vice President, Clinical Development, Anergen, where he completed first-in-human clinical trials of novel biologics for DMARD-refractory rheumatoid arthritis or secondary progressive multiple sclerosis. He contributed expertise to more than 20 biopharmaceutical companies and CROs such as Sandoz, Syntex, Genentech, Chiron, Alza, SangStat, Anergen, Neurobiological Technologies, Celtic Pharmaceutical Holdings, CTI Clinical Trial & Consulting Services, Research Pharmaceutical Services, and PRA Health Sciences. He is an Emeritus Member of the American College of Rheumatology, the American Society of Nephrology, the American Society of Transplantation, and the Society for Neuro-oncology.
Michael is an experienced and versatile leader in translational medical/scientific research, as well as the design and execution of clinical trials. He has a track record of successful collaboration with academic investigators and Key Opinion Leaders, medical monitoring of global clinical trials, accompanied by positive FDA interactions and regulatory document submissions.
An MD graduate of Columbia University’s College of Physicians & Surgeons, board-certified in Internal Medicine, with subspecialty training and expertise in Nephrology, Michael was Assistant Professor of Medicine (Nephrology), Emory University School of Medicine, directed three freestanding dialysis centers, and is currently licensed in California.
Stephen T. Adams JD – General Counsel
Stephen T. Adams is General Counsel of Pharma Capital Partners. He oversees legal operations of the management company, its funds and related entities. He also reviews deal negotiations, investment and exit structuring, as well as development and implementation of IP strategies.
Stephen has practiced corporate law in the life sciences, technology and private equity sectors for 20+ years, representing public and private companies, investment banks, venture capital funds, private equity funds and hedge funds. He has been a partner at two international law firms (Greenberg Traurig LLP and Goodwin Procter LLP), where he advised issuers and investors in traditional securities transactions and alternative investment structures in virtually all major global markets.
Prior to joining PCP, Stephen worked at Wellington Management Company LLP, a global asset management firm with $1T in assets under management, building its private equity business.
Stephen received a BS degree from the University of Connecticut, an MS degree from the University of North Dakota, and a JD from the University of Virginia School of Law. Prior to attending law school, Stephen served on active duty in the United States Air Force, attaining the rank of Major.
Ashok Srivastava, MD, PhD, MBA - Scientific & Medical Advisory Board Member
Dr. Ashok Srivastava is currently Chief Executive Officer and Chief Medical Officer of ClinFomatrix, a global Contract Research Organization (CRO). He has 19+ years of experience in Phase I-4 drug development, Medical Affairs as well as launch, marketing and commercialization of cancer drugs and radiopharmaceutical products for solid and hematologic cancer in USA, EU, and Japan. Dr. Srivastava has been a leader in global development of cancer drugs, including large and complex Phase 3 clinical trials. Highly experienced in the regulatory process in the major global pharmaceutical markets, moreover, he made significant contributions to 21 INDs and 7 NDAs for cancer drugs.
Dr. Srivastava received his clinical, medical and business education from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Nagasaki, Japan, and Rutgers University Business School, USA. He subsequently worked at renowned medical centers and pharmaceutical institutions worldwide, such as Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai Oncology, and Spectrum Pharmaceuticals. He played a key role in major label expansion of oncology drugs such as Sutent® (Sunitinib), Evoxac® (Cevimeline-HCl), and Myocet® (liposomal doxorubicin in combination with Herceptin & Paclitaxel for metastatic HER2 positive breast cancer), and Latuda® (Lurasidone) – an atypical antipsychotic for schizophrenia. He is one of the inventors of the Japanese encephalitis vaccine (IXIARO®). Dr. Srivastava is a leader in drug safety, pharmacovigilance, hematology, and immuno-oncology. He brought four cancer drugs and one vaccine to global markets with approx. $3.5 billion in global sales.
A named inventor on two patents, he has received awards from United Nations, Ministry of Health in Japan, and Department of the Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research in USA. He is a member of numerous organizations -- America’s Top Oncologist of the years 2007, 2008, 2011, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer.